Candriam SCA’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2024
Q3
Sell
-317,509
Closed -$11.8M 690
2024
Q2
$11.8M Hold
317,509
0.07% 235
2024
Q1
$13.3M Hold
317,509
0.09% 221
2023
Q4
$12.6M Sell
317,509
-5,000
-2% -$198K 0.09% 224
2023
Q3
$8.88M Sell
322,509
-228,000
-41% -$6.27M 0.06% 239
2023
Q2
$18.7M Sell
550,509
-45,000
-8% -$1.53M 0.14% 170
2023
Q1
$19.7M Buy
595,509
+107,000
+22% +$3.54M 0.14% 170
2022
Q4
$21.8M Buy
488,509
+70,000
+17% +$3.12M 0.15% 159
2022
Q3
$11.8M Buy
418,509
+127,715
+44% +$3.59M 0.08% 233
2022
Q2
$7.84M Buy
290,794
+13,313
+5% +$359K 0.06% 263
2022
Q1
$9.45M Sell
277,481
-109,740
-28% -$3.74M 0.06% 265
2021
Q4
$15M Buy
387,221
+206,999
+115% +$8M 0.1% 209
2021
Q3
$9.73M Sell
180,222
-219,463
-55% -$11.8M 0.07% 277
2021
Q2
$13.4M Buy
399,685
+55,546
+16% +$1.86M 0.09% 243
2021
Q1
$5.79M Hold
344,139
0.05% 348
2020
Q4
$6.03M Buy
+344,139
New +$6.03M 0.05% 357
2016
Q1
Sell
-5,733
Closed -$1.35M 638
2015
Q4
$1.35M Sell
5,733
-3,034
-35% -$713K 0.04% 350
2015
Q3
$1.39M Sell
8,767
-2,233
-20% -$353K 0.03% 390
2015
Q2
$4.16M Sell
11,000
-667
-6% -$252K 0.09% 268
2015
Q1
$4.88M Buy
11,667
+2,334
+25% +$976K 0.1% 258
2014
Q4
$2.56M Buy
+9,333
New +$2.56M 0.05% 326